Genedata Selector is committed to facilitating the exchange of knowledge and discussion of best practices of Next-Generation Sequencing (NGS) for cell and gene therapy development, biosafety testing and cell line development. To this end, Genedata Selector regularly hosts exclusive community-building industry workshops with leading biopharmaceutical companies, featuring expert presentations and discussions on key industry challenges and opportunities to learn and share perspectives.
Our most recent Open Forum with Astellas focused on product development and characterization for cell and gene therapies. With Sarepta Therapeutics, we held one event focusing on NGS-based assays for AAV vector production and characterization, multi-attribute method (MAM) approaches, and biosafety. With Bristol Myers Squibb (BMS), we held four events focusing on NGS-based biosafety testing and its benefits for biopharma R&D and regulatory practices. We also held two events with Boehringer Ingelheim, focusing on NGS-based cell line development (CLD). These events provided a platform for subject matter experts to share their experiences in cell line characterisation, multi-omics data integration and analysis.